Biocon Malaysia Receives MHRA Approval for New Drug Product Fill Finish Unit for Insulins

  • Posted by: Biocon Biologics

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Bengaluru, Karnataka, India, September 25, 2026

Biocon Limited (BSE code: 532523, NSE: BIOCON) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug product fill finish unit for Semglee® (insulin glargine) at its insulin manufacturing facility in Malaysia.

In July, Biocon had secured regulatory approval from the European Medicines Agency (EMA) for this new drug product fill-finish line.

Author: Biocon Biologics